here comes the money

We are planning to conduct an underwritten public offering to sell up to 5,200,000 shares of our
common stock (equivalent to 1,040,000,000 CDIs) for cash and filed a registration statement on
Form S-1 registering shares of common stock on July 17, 2012. The issue price for shares sold in the
offering will be determined by negotiations between us and the underwriters and will be based on,
among other factors, our past and present operating results, recent prices for shares of our common
stock on the Nasdaq Capital Market and of our CDIs on the ASX, our future prospects and those of
the medical device industry in general, general market and economic conditions, regulatory milestones
achieved in our clinical trials, and certain financial and operating information of companies engaged in
activities similar to ours.